1 中信证券股份有限公司（以下简称"中信证券"）受山东威高骨科材料股份 有限公司（以下简称"威高骨科"）股东山东省财金投资集团有限公司委托，组 织实施本次威高骨科首发前股东向特定机构投资者询价转让（以下简称"本次询 价转让"）。 中信证券股份有限公司 关于山东威高骨科材料股份有限公司股东 向特定机构投资者询价转让股份 相关资格的核查意见 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创 板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下 简称"《询价转让和配售指引》"）等相关规定，中信证券对参与本次询价转让 股东的相关资格进行核查，并出具本核查意见。 一、本次询价转让的委托 根据相关法规要求，中信证券对出让方的相关资格进行了核查。出让方已出 具《关于向特定机构投资者询价转让首次公开发行前已发行股份出让方资格相关 事宜的承诺函》。中信证券已于 2024 年 12 月 16 日完成出让方资格核查工作， 对出让方进行访谈和问询，并收集相关核查 ...

证券代码：688161 证券简称：威高骨科 公告编号：2024-054 山东威高骨科材料股份有限公司 2024 年第三季度权益分派实 施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利 0.05 元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/12/11 | 2024/12/12 | 2024/12/12 | 一、 通过分配方案的股东大会届次和日期 经公司 2024 年 4 月 29 日召开的 2023 年年度股东大会授权董事会在符合利润 分配的条件下制定具体的 2024 年度中期分红的具体方案，公司于 2024 年 10 月 29 日召开了第三届董事会第十二次会议，审议通过本次利润分配方案。 公司已于 2024 年 10 月 31 日就本次利润分配方案发布了《山东威高骨科材料 股份有限公司关于进行 2024 年第二次中期分红的公告》。 二、 分配方案 1. 发放年度：2024 年第三季度 2. 分派对象： 截至股 ...

Investment Rating - The report assigns an "Overweight" rating to Weigao Orthopedics (688161 SH) for the first time [3][7] Core Views - Weigao Orthopedics' revenue and net profit have fully recovered and exceeded expectations in Q3 2024 [3] - Q1-Q3 revenue reached RMB 1 083 million up 0 07% YoY - Q1-Q3 net profit attributable to shareholders reached RMB 164 million up 34 66% YoY - Q3 revenue reached RMB 333 million up 20 06% YoY - Q3 net profit attributable to shareholders reached RMB 71 1633 million up 594 19% YoY - The company has significantly improved its sales and distribution capabilities with multiple product lines showing substantial sales growth [4] - Spine product line sales volume increased 36 17% YoY in Q1-Q3 - Trauma product line sales revenue increased 16 25% and sales volume increased 18 45% YoY in Q1-Q3 - Joint product line sales revenue increased 23 12% and sales volume increased over 27 37% YoY in Q1-Q3 - Sports medicine product line sales revenue reached RMB 28 538 million up over 11 times YoY in Q1-Q3 - The company is actively expanding overseas business with rapid growth [5] - Overseas trade increased 52% YoY - Focused on regional strategies and product registration in key countries - The company has diversified its R&D layout with multiple new products approved [6] - New products include "Occipitocervicothoracic Posterior Spinal Fixation System" "Plasma Surgical Equipment" and "Disposable Annulus Fibrosus Suture Device" Financial Forecasts - Revenue and profit projections for 2024-2026 [7][10] - 2024E revenue: RMB 1 418 million (+10 4% YoY) - 2025E revenue: RMB 1 680 million (+18 5% YoY) - 2026E revenue: RMB 2 016 million (+20 0% YoY) - 2024E net profit attributable to shareholders: RMB 232 million (+106 9% YoY) - 2025E net profit attributable to shareholders: RMB 310 million (+33 5% YoY) - 2026E net profit attributable to shareholders: RMB 360 million (+16 1% YoY) - Valuation metrics [7][10] - 2024E EPS: RMB 0 58 - 2025E EPS: RMB 0 78 - 2026E EPS: RMB 0 90 - 2024E PE: 49 69x - 2025E PE: 37 22x - 2026E PE: 32 07x Financial Performance - Key financial indicators for 2023A and 2024-2026E [10][13] - Gross margin: 66 5% (2023A) 64 7% (2024E) 64 5% (2025E) 64 4% (2026E) - ROE: 2 9% (2023A) 5 8% (2024E) 7 4% (2025E) 8 1% (2026E) - Net profit margin: 8 8% (2023A) 16 4% (2024E) 18 5% (2025E) 17 9% (2026E) - ROIC: 4 5% (2023A) 10 1% (2024E) 12 0% (2025E) 14 6% (2026E)

北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 2024 年第三次临时股东大会的 法律意见书 二〇二四年十一月 北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 2024 年第三次临时股东大会的 法律意见书 本次会议采用现场投票和网络投票相结合的方式进行。本次会议的现场会议 于 2024 年 11 月 20 日 14:50 在山东威高骨科材料股份有限公司会议室（威海市 旅游度假区香江街 26 号）召开。公司股东通过交易系统投票平台投票的时间为 2024 年 11 月 20 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过互联网投票平台投 票的时间为 2024 年 11 月 20 日 9:15-15:00。 本所认为，本次股东大会的召集和召开程序符合《公司法》《股东大会规则》 和《公司章程》的规定。 二、本次股东大会的召集人资格 法律意见书 致：山东威高骨科材料股份有限公司 根据中国证监会发布的《上市公司股东大会规则》（下称"《股东大会规则》"） 的有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受山东威高骨 科材料股份有限公司（下称"公司"） ...

证券代码：688161 证券简称：威高骨科 公告编号：2024-053 山东威高骨科材料股份有限公司 2024 年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 二、 议案审议情况 （一） 非累积投票议案 1、 议案名称：《关于公司拟聘请会计师事务所的议案》 审议结果：通过 （一） 股东大会召开的时间：2024 年 11 月 20 日 （二） 股东大会召开的地点：山东威高骨科材料股份有限公司会议室（威海市 旅游度假区香江街 26 号） （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 88 | | --- | --- | | 普通股股东人数 | 88 | | 2、出席会议的股东所持有的表决权数量 | 352,018,890 | | 普通股股东所持有表决权数量 | 352,018,890 | | 3、出席会议的股东所持有表决权数量占公司表决权 ...

证券代码：688161 证券简称：威高骨科 山东威高骨科材料股份有限公司 2024 年第三次临时股东大会 会议资料 二零二四年十一月 | 2024 | 年第三次临时股东大会会议须知 1 | | --- | --- | | 2024 | 年第三次临时股东大会会议议程 3 | | 2024 | 年第三次临时股东大会会议议案 5 | | | 关于公司拟聘请会计师事务所的议案 5 | 山东威高骨科材料股份有限公司 2024 年第三次临时股东大会会议资料 2024 年第三次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保 证大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东大会规则》以及《山东威高骨科材料股份有限公司章程》等相 关规定，山东威高骨科材料股份有限公司（以下简称"公司"）特制定 2024 年 第三次临时股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议人员的身份进行必要的核对工作，请被核对者给予配合。 出席会议的股东及股东代理人须在会议召开前 30 分钟到会议现场办理签到 手续，并请 ...

Investment Rating - The report maintains a "Buy" rating for the company [1][3] Core Insights - The company reported a total revenue of 1.083 billion yuan for the first three quarters of 2024, reflecting a slight increase of 0.07% year-on-year, and a net profit attributable to shareholders of 164 million yuan, which is a significant increase of 34.66% [2] - In Q3 alone, the company achieved a revenue of 333 million yuan, representing a year-on-year growth of 20.06%, while the net profit for the quarter surged by 594.19% to 71 million yuan [2][3] - The gross margin for Q3 was 66.01%, with a net margin of 21.72%, showing improvements in profitability despite slight fluctuations in gross margin due to market dynamics [3] Financial Forecasts and Valuation - The company is expected to see a gradual increase in market share and stable growth in performance, with projected net profits of 231 million yuan, 351 million yuan, and 415 million yuan for 2024, 2025, and 2026 respectively [3] - Corresponding P/E ratios for these years are estimated at 51, 34, and 29 times, indicating a favorable valuation outlook [3] - The report highlights a decrease in sales expense ratio, contributing to the recovery of net profit margins [3] Revenue and Profit Trends - The total revenue forecast for the company is set to increase from 1.284 billion yuan in 2023 to 2.077 billion yuan by 2026, with a compound annual growth rate (CAGR) of approximately 20.80% [1][9] - The net profit is projected to grow from 112 million yuan in 2023 to 415 million yuan in 2026, reflecting a robust growth trajectory [1][9] Market Data - The company's closing price is reported at 29.74 yuan, with a market capitalization of approximately 11.896 billion yuan [5] - The stock has experienced a price range between 18.54 yuan and 43.34 yuan over the past year [5]

证券代码：688161 券简称：威高骨科 公告编号：2024-051 山东威高骨科材料股份有限公司 第三届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东威高骨科材料股份有限公司（以下简称"公司"）第三届董事会第十二 次会议于 2024 年 10 月 29 日以现场及通讯相结合的方式召开。本次会议应出席 董事 9 人，实际出席董事 9 人，会议由董事长陈敏女士主持，本次董事会会议的 召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法、有效。 二、董事会会议审议情况 1、审议通过《关于公司<2024 年第三季度报告>的议案》 公司董事会认为：公司《2024 年第三季度报告》的编制和审议程序符合法 律、法规、《公司章程》和公司内部管理制度的各项规定；公司《2024 年第三季 度报告》的内容与格式符合中国证券监督管理委员会和上海证券交易所的各项规 定，能够公允地反映公司报告期内的财务状况和经营成果。董事会及全体董事保 证公司《2024 ...

Revenue and Profit Performance - Revenue for the third quarter was RMB 332.74 million, a 20.06% increase compared to the same period last year[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 71.16 million, a 594.19% increase year-over-year[2] - The company achieved a revenue of RMB 1,083.28 million in the first three quarters, a year-on-year increase of 0.07%, and a net profit attributable to shareholders of RMB 164.29 million, a year-on-year increase of 34.66%[11] - In the third quarter, the company achieved a revenue of RMB 332.74 million, a year-on-year increase of 20.06%, and a net profit attributable to shareholders of RMB 71.16 million, a year-on-year increase of 594.19%[11] - Total operating revenue for the first three quarters of 2024 was RMB 1,083,278,467.47, a slight increase from RMB 1,082,526,944.91 in the same period of 2023[22] - Net profit attributable to the parent company's shareholders in the first three quarters of 2024 was RMB 164,293,158.99, compared to RMB 122,008,305.50 in the same period of 2023, representing a growth of 34.7%[23] - The increase in revenue was primarily due to higher sales volume compared to the same period last year[6] Earnings Per Share and Return on Equity - Basic earnings per share for the third quarter were RMB 0.18, a 500% increase compared to the same period last year[2] - Diluted earnings per share for the third quarter were RMB 0.18, a 500% increase compared to the same period last year[3] - Weighted average return on equity for the third quarter was 1.82%, an increase of 1.56 percentage points compared to the same period last year[3] - Basic earnings per share for the first three quarters of 2024 were RMB 0.41, up from RMB 0.31 in the same period of 2023, reflecting a 32.3% increase[24] R&D and Sales Expenses - R&D investment for the third quarter was RMB 27.51 million, accounting for 8.27% of revenue, a decrease of 0.72 percentage points compared to the same period last year[3] - R&D expenses for the first three quarters of 2024 increased to RMB 91,157,022.54, up from RMB 86,638,389.02 in the same period of 2023, reflecting a 5.2% increase[22] - The company's sales expense ratio decreased by 9 percentage points year-on-year due to optimized marketing organization and personnel structure, channel integration, and refined expense management[12] - Sales expenses decreased to RMB 371,892,305.06 in the first three quarters of 2024, down from RMB 468,100,649.76 in the same period of 2023, a reduction of 20.6%[22] Product Line Performance - The spine product line achieved sales revenue of RMB 331 million in the first three quarters, a year-on-year decrease of 16.23%, with sales volume increasing by 36.17%[12] - The trauma product line achieved sales revenue of RMB 188 million in the first three quarters, a year-on-year increase of 16.25%, with sales volume increasing by 18.45%[12] - The joint product line achieved sales revenue of RMB 300 million in the first three quarters, a year-on-year increase of 23.12%, with sales volume increasing by over 27.37%[13] - The sports medicine product line achieved sales revenue of RMB 28.54 million in the first three quarters, a year-on-year increase of over 11 times[14] - The tissue repair product line achieved sales revenue of approximately RMB 130 million in the first three quarters, a year-on-year increase of 20.49%, with sales volume increasing by 65.74%[14] - The company's quantum medical revenue reached approximately 24 million yuan, a year-on-year increase of over 3 times[15] Assets and Liabilities - Total assets at the end of the reporting period were RMB 5.02 billion, a 1.56% decrease compared to the end of the previous year[3] - The company's total assets amounted to 5,017,260,766.83 yuan, with current assets totaling 4,241,592,416.03 yuan[19] - The company's total liabilities were 1,094,005,081.86 yuan, with current liabilities accounting for 967,428,423.95 yuan[20] - The company's fixed assets were valued at 441,498,720.68 yuan, showing a decrease from the previous period[19] - The company's inventory was valued at 743,556,501.84 yuan, slightly decreasing from the previous period[19] - Total equity attributable to the parent company's shareholders as of the end of Q3 2024 was RMB 3,913,925,667.34, compared to RMB 3,868,918,255.96 at the end of Q3 2023, showing a 1.2% increase[21] - The company's total liabilities and equity as of the end of Q3 2024 were RMB 5,017,260,766.83, slightly lower than RMB 5,096,573,977.62 at the end of Q3 2023, a decrease of 1.6%[21] Cash Flow and Financial Activities - Net cash flow from operating activities for the period from the beginning of the year to the end of the reporting period was RMB 189.84 million, a 103.67% increase year-over-year[2] - Operating cash flow increased to 189.84 million yuan, up 103.7% year-over-year from 93.21 million yuan[26] - Investment cash inflow totaled 859.48 million yuan, with 840 million yuan from investment recoveries[26] - Investment cash outflow reached 864.66 million yuan, including 852 million yuan for new investments[26] - Financing cash outflow was 87.51 million yuan, with 47.99 million yuan allocated for dividend and interest payments[27] - Net cash and cash equivalents increased by 105.71 million yuan, compared to a decrease of 925.03 million yuan in the same period last year[27] - End-of-period cash and cash equivalents stood at 1.92 billion yuan, up from 1.78 billion yuan at the end of the previous period[27] - Tax refunds received amounted to 2.29 million yuan, a decrease from 14.97 million yuan in the previous year[26] - Cash received from other operating activities was 23.17 million yuan, down from 90.26 million yuan year-over-year[26] - Cash paid for employee compensation was 250.07 million yuan, slightly lower than the 254.44 million yuan in the previous year[26] - Cash paid for taxes and fees decreased to 90.44 million yuan from 225.29 million yuan year-over-year[26] - Cash received from sales of goods and services in the first three quarters of 2024 was RMB 1,244,264,410.31, a decrease from RMB 1,349,627,802.79 in the same period of 2023, representing a 7.8% decline[25] Government Subsidies and Other Income - Government subsidies included in current profits amounted to RMB 1.52 million for the third quarter[4] Overseas Business and Trade - The company's overseas trade grew by 52% year-on-year, with rapid expansion in overseas business[17] Product Approvals and Innovations - The company's "plasma surgery equipment" was approved by the National Medical Products Administration, enriching the minimally invasive treatment product line[16] - The company's "one-time use annulus suture device" was approved, enhancing post-surgery stability and reducing recurrence rates[16] - The company's "occipital-cervical-thoracic spine posterior fixation system" was approved, offering flexible configurations and superior biomechanical performance[15] Production and Operational Efficiency - The company optimized production capacity and improved manufacturing efficiency through scientific equipment allocation[17] Comprehensive Income - Total comprehensive income for the first three quarters of 2024 was RMB 168,426,611.66, compared to RMB 121,877,124.55 in the same period of 2023, showing a 38.2% growth[23]

山东威高骨科材料股份有限公司 相关事项的独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 科创板股票上市规则(2024年4月修订)》及《公司章程》等的相关规定，作为 山东威高骨科材料股份有限公司(以下简称"公司")的独立董事,本着谨慎性 的原则,基于独立判断立场,对公司第三届董事会第十二次会议相关事项发表独 立意见如下: 一、《关于拟聘请会计师事务所的议案》的独立意见 经审议,我们认为:致同会计师事务所(特殊普通合伙)具备证券相关业务 资格,具有多年为上市公司提供审计服务的经验,能够为公司提供真实、准确、 客观、公正的审计服务,满足公司 2024 年度财务审计及内部控制审计工作要求。 公司本次聘请会计师事务所的审议程序符合法律、法规和《公司章程》的有关规 定,不存在损害公司及全体股东,特别是中小股东利益的情形。 综上,我们一致同意聘任致同会计师事务所（特殊普通合伙）为公司 2024 年度财务报告和内部控制审计机构，并同意将该议案提交公司 2024 年第三次临 时股东大会审议。 二、《关于进行 2024年三季度中期分红的议案》的独立意见 为进一步提高分红频次，增强投资者回报水平，公 ...